(Reuters) – Eli Lilly and Co (N:) reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.
Net income rose to $1.25 billion, or $1.37 per share, in the quarter ended Sept. 30, from $1.15 billion, or $1.12 per share, a year earlier.
Revenue rose 3.2% to $5.48 billion.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.